Sorrento Therapeutics announced that the company’s COVID-19 treatment Covishield (STI-9167) shows significant progress in neutralizing Omicron and Omicron variants of SARS-COV-2.
If you are not happy with the results below please do another search
50 search results for:
GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.
Pfizer Inc. said on January 21 the U.S. health regulator declined to approve somatrogon as a treatment for growth hormone deficiency in children that the company developed with partner Opko Health Inc.
The United States – the World Health Organization’s top donor – is resisting proposals to make the agency more independent, four officials involved in the talks said, raising doubts about the Biden administration’s long-term support for the U.N. agency.
The U.S. Food and Drug Administration lifted the partial hold on Kura Oncology’s clinical trial on a potential treatment for acute myeloid leukemia (AML).
The World Health Organization on January 21 recommended extending the use of a reduced dosage of Pfizer’s COVID-19 vaccine to children aged 5 to 11 years old.
The Glycogen Storage Disease Program at Connecticut Children’s and UConn Health reported success in a Phase I/II trial of a gene therapy for GSD-Ia. The gene therapy is developed with Ultragenyx and is dubbed DTX401.
Led by new CEO Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals has a stated ambition to transition the RNA interference therapeutics trailblazer to a top 5 biotech – measured by market capitalization – within the next five years.
Visionary tech magnate Elon Musk is taking his neurotech company to the next step toward in-human trials of his implantable brain-machine interface.
New coronavirus cases are falling in parts of the United States hit hardest by the fast-spreading Omicron variant, according to a Reuters analysis of public health data, offering an early indication the virus might once again be in retreat.